Michael Rosario-Prieto, MD
Neuromuscular Medicine · St Petersburg, FLNPI 1871738948
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,292 of the $167,084 with a category attached, or 73.8%. UCB, Inc. accounts for 61.2% of it on its own, with 59 other manufacturers making up the rest.
Across 833 payments — averaging $200.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$102K
- Argenx US, Inc.$45K
- UCB SA$4K
- Amgen$2K
- AbbVie$2K
- AstraZeneca$2K
- plus $10K from 54 others
Across 39 payments — averaging $7805.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$304K
What the payments were for
- Consulting fees$14,5359%
- Speaking & faculty fees$123,29274%
- Travel & lodging$11,5847%
- Food & beverage$17,41110%
- Education$2620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zilbrysq$56,518
- Rystiggo$45,361
- VYVGART$42,047
- UPLIZNA$2,200
- SOLIRIS$964
- EVRYSDI$140
- ENROUTE Transcarotid Neuroprotection System$138
- ENROUTE Transcarotid Stent System$138
- ENHANCE Transcarotid Peripheral Access Kit$138
- ENROUTE 0.014 Guidewire$138
- UBRELVY$122
- XCOPRI$116
How this compares
Too few neuromuscular medicine providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZilbrysqZilucoplan Sodium | 25 | $930,653 |
| Radicava OrsEdaravone | 36 | $506,244 |
| EvrysdiRisdiplam | 14 | $375,870 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 54 | $306,371 |
| EmflazaDeflazacort | 13 | $198,759 |
| Aimovig AutoinjectorErenumab-Aooe | 85 | $77,186 |
| BotoxOnabotulinumtoxina | 28 | $34,564 |
| Nurtec OdtRimegepant Sulfate | 29 | $31,776 |
| UbrelvyUbrogepant | 23 | $27,529 |
| QuliptaAtogepant | 17 | $19,654 |
| EliquisApixaban | 22 | $12,563 |
| Emgality PenGalcanezumab-Gnlm | 14 | $12,180 |
| Pyridostigmine Bromide | 105 | $9,051 |
| Gabapentin | 247 | $3,990 |
| Sumatriptan Succinate | 57 | $3,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Zilbrysq | $102,217 | $930,65325 claims |
| Genentech USA, Inc.Evrysdi | $570 | $375,87014 claims |
| Grifols USA, LLCGamunex-C | $79 | $306,37154 claims |
| AbbVieBotox, Ubrelvy, Qulipta | $1,905 | $81,74868 claims |
| PfizerNurtec Odt, Eliquis | $527 | $44,33951 claims |
| Upsher-smith Laboratories LLCTopiramate | $106 | $30434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other neuromuscular medicine in St Petersburg
- Amparo GutierrezOrlando$810K
- Manisha KorbWest Palm Beach$328K
- James WymerGainesville$33K
- Cole LinvilleJacksonville$32K
- Michael TodincaJacksonville Beach$16K
- Sara HuserWest Palm Beach$9K
- Naga Lakshmana NidadavoluSaint Cloud$9K
- Nathan CarberryMiami$5K
- Clifton GoochTampa$5K
- Kyle RuffingGainesville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.